Brown Advisory Inc. Has $1.17 Million Stock Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Brown Advisory Inc. lowered its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 33.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,119 shares of the pharmaceutical company's stock after selling 15,157 shares during the period. Brown Advisory Inc.'s holdings in GSK were worth $1,167,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Columbia Asset Management bought a new position in GSK during the fourth quarter valued at approximately $233,000. Brighton Jones LLC bought a new position in shares of GSK during the 4th quarter valued at $528,000. Stamos Capital Partners L.P. lifted its stake in shares of GSK by 42.3% in the 4th quarter. Stamos Capital Partners L.P. now owns 294,820 shares of the pharmaceutical company's stock valued at $9,971,000 after purchasing an additional 87,630 shares during the last quarter. First Hawaiian Bank boosted its holdings in GSK by 18.8% in the first quarter. First Hawaiian Bank now owns 101,039 shares of the pharmaceutical company's stock worth $3,914,000 after purchasing an additional 15,987 shares in the last quarter. Finally, FMR LLC boosted its holdings in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of NYSE GSK traded down $0.19 during trading hours on Tuesday, hitting $38.10. 2,135,045 shares of the company's stock were exchanged, compared to its average volume of 5,180,669. The company's 50-day moving average price is $38.97 and its 200-day moving average price is $37.33. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The stock has a market capitalization of $78.00 billion, a price-to-earnings ratio of 19.64, a PEG ratio of 1.54 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The company had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same period in the previous year, the business posted $0.43 EPS. The company's revenue for the quarter was up 2.1% on a year-over-year basis. On average, sell-side analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were paid a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.43%. The ex-dividend date of this dividend was Friday, May 16th. GSK's dividend payout ratio is presently 88.14%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GSK. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res raised GSK to a "strong sell" rating in a research note on Monday, April 28th. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, BNP Paribas initiated coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.